MannKind reports positive Afrezza® clinical data from Type 1 diabetes study
MannKind Corp. announced that data from a one-year study of Afrezza® (insulin human) Inhalation Powder. MannKind investigators reported data1 from more than 500 patients with type 1 diabetes comparing Afrezza to rapid-acting injected insulin analog (insulin aspart) therapy to assess glucose control. September 19, 2019